Alan L Epstein, MD, PhD

Title(s)Professor of Pathology
SchoolKeck School of Medicine of Usc
AddressHMR 2011 Zonal Ave
Health Sciences Campus
Los Angeles CA 90089-9092
Phone+1 323 442 1172
vCardDownload vCard
    Other Positions
    Title(s)Pharmacology and Pharmaceutical Sciences, of the USC Mann School of Pharmacy

    Collapse Overview 
    Collapse Overview
    Alan L. Epstein MD, PhD is a Professor at the Keck School of Medicine at the University of Southern California and has over 30 years of experience in the laboratory developing monoclonal antibodies and other reagents for the treatment of cancer. He has published over 150 papers in the field and has filed 25 patents including those describing the use of TNT antibodies for the imaging and therapy of cancer. Along with TNT antibodies, Dr. Epstein has invented the Lym-1 antibody for the treatment of lymphoma, vasopermeability enhancing antibodies to increase the uptake of drugs and antibodies in tumors, the LN panel of diagnostic antibodies, and most recently several novel fusion proteins for the immunotherapy of cancer. He has been a consultant for numerous biotechnology companies and is an accomplished speaker and scientist in his field. Dr. Epstein holds a bachelor’s degree in biology from Wesleyan University, Middletown, CT and obtained the MD and PhD degrees from the Medical Scientist Training Program at Stanford University School of Medicine. Before coming to the University of Southern California, Dr. Epstein started his academic career in the Department of Medicine, Division of Medical Oncology at the Northwestern University School of Medicine in Chicago.
    Collapse Websites

    Collapse Research 
    Collapse Research Activities and Funding
    Monoclonal Antibodies Against T-Regulatory Cells
    NIH R41CA109884Aug 1, 2004 - Jul 31, 2006
    Role: Principal Investigator
    NIH R01CA083001Feb 1, 2000 - Jan 31, 2004
    Role: Principal Investigator
    NIH R01CA049987Dec 5, 1990 - Nov 30, 1993
    Role: Principal Investigator
    NIH R01CA047334Apr 1, 1988 - May 31, 1995
    Role: Principal Investigator
    NIH R01CA040608Jul 1, 1985 - Jun 30, 1988
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Faculty Mentoring
    Collapse Required Scholarly Project Mentor

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Enhancing brain entry and therapeutic activity of chimeric antigen receptor T cells with intra-arterial NEO100 in a mouse model of CNS lymphoma. J Neurosurg. 2023 Dec 29; 1-9. Wang W, He H, Zheng L, Zeng S, Cho HY, Kouhi A, Khawli LA, Chen L, Stathopoulos A, Schönthal AH, Epstein AL, Chen TC. PMID: 38157532.
      View in: PubMed   Mentions: 1     Fields:    
    2. Immune Priming with Spatially Fractionated Radiation Therapy. Curr Oncol Rep. 2023 Dec; 25(12):1483-1496. Lukas L, Zhang H, Cheng K, Epstein A. PMID: 37979032; PMCID: PMC10728252.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Enhanced brain entry of checkpoint-inhibitory therapeutic antibodies facilitated by intraarterial NEO100 in mouse models of brain-localized malignancies. J Neurosurg. 2023 09 01; 139(3):822-830. Wang W, He H, Zeng S, Cho HY, Minea RO, Swenson SD, Zheng L, Epstein AL, Stathopoulos A, Chen L, Schönthal AH, Chen TC. PMID: 36738464.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    4. The anticancer effects of Metformin in the male germ tumor SEM-1 cell line are mediated by HMGA1. Front Endocrinol (Lausanne). 2022; 13:1051988. Salatino A, Mirabelli M, Chiefari E, Greco M, Di Vito A, Bonapace G, Brunetti FS, Crocerossa F, Epstein AL, Foti DP, Brunetti A. PMID: 36506071; PMCID: PMC9727077.
      View in: PubMed   Mentions: 6     Fields:    
    5. Deletion of monoamine oxidase A in a prostate cancer model enhances anti-tumor immunity through reduced immune suppression. Biochem Biophys Res Commun. 2022 12 17; 634:100-107. Lapierre JA, Geary LA, Jang JK, Epstein AL, Hong F, Shih JC. PMID: 36242915.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    6. Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes. Mol Ther. 2022 09 07; 30(9):3066-3077. Cheng Q, Dai Z, Smbatyan G, Epstein AL, Lenz HJ, Zhang Y. PMID: 35746867; PMCID: PMC9481992.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    7. Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppression. Blood. 2022 06 02; 139(22):3290-3302. Cao X, Wang Y, Zhang W, Zhong X, Gunes EG, Dang J, Wang J, Epstein AL, Querfeld C, Sun Z, Rosen ST, Feng M. PMID: 35134139; PMCID: PMC9164740.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    8. Restoration of Follicular T Regulatory/Helper Cell Balance by OX40L-JAG1 Cotreatment Suppresses Lupus Nephritis in NZBWF1/j Mice. J Immunol. 2022 06 01; 208(11):2467-2481. Kumar P, Balakrishnan S, Surendra Lele S, Setty S, Dhingra S, Epstein AL, Prabhakar BS. PMID: 35470257.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    9. NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor Microenvironment. Mol Cancer Ther. 2021 12; 20(12):2384-2397. Dong T, Dave P, Yoo E, Ebright B, Ahluwalia K, Zhou E, Asante I, Salimova M, Pei H, Lin T, Mead A, Li Z, Humayun M, Petasis NA, Epstein AL, Louie SG. PMID: 34607931.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    10. Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model. Sci Rep. 2021 07 23; 11(1):15077. Sta Maria NS, Khawli LA, Pachipulusu V, Lin SW, Zheng L, Cohrs D, Liu X, Hu P, Epstein AL, Jacobs RE. PMID: 34302002; PMCID: PMC8302724.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    11. Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives. Int J Mol Sci. 2021 Jun 16; 22(12). Kouhi A, Pachipulusu V, Kapenstein T, Hu P, Epstein AL, Khawli LA. PMID: 34208575; PMCID: PMC8235515.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    12. Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma. Haematologica. 2021 06 01; 106(6):1714-1724. Oishi N, Hundal T, Phillips JL, Dasari S, Hu G, Viswanatha DS, He R, Mai M, Jacobs HK, Ahmed NH, Syrbu SI, Salama Y, Chapman JR, Vega F, Sidhu J, Bennani NN, Epstein AL, Medeiros JL, Clemens MW, Miranda RN, Feldman AL. PMID: 32414854; PMCID: PMC8168507.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimals
    13. NEO100 enables brain delivery of blood‒brain barrier impermeable therapeutics. Neuro Oncol. 2021 01 30; 23(1):63-75. Wang W, Marín-Ramos NI, He H, Zeng S, Cho HY, Swenson SD, Zheng L, Epstein AL, Schönthal AH, Hofman FM, Chen L, Chen TC. PMID: 32877532; PMCID: PMC7850137.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    14. Adopting an alternative structure for clinical trials in immunotherapy. Expert Rev Anticancer Ther. 2021 04; 21(4):373-375. Roussos Torres ET, Epstein AL. PMID: 33435760.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    15. Nuclear Localization of PTTG1 Promotes Migration and Invasion of Seminoma Tumor through Activation of MMP-2. Cancers (Basel). 2021 Jan 08; 13(2). Teveroni E, Di Nicuolo F, Bianchetti G, Epstein AL, Grande G, Maulucci G, De Spirito M, Pontecorvi A, Milardi D, Mancini F. PMID: 33430117; PMCID: PMC7826632.
      View in: PubMed   Mentions: 7  
    16. Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma. Oncoimmunology. 2021 01 04; 10(1):1838140. Shirinbak S, Chan RY, Shahani S, Muthugounder S, Kennedy R, Hung LT, Fernandez GE, Hadjidaniel MD, Moghimi B, Sheard MA, Epstein AL, Fabbri M, Shimada H, Asgharzadeh S. PMID: 33489468; PMCID: PMC7801125.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    17. Spontaneous Intraparenchymal Hepatic Hemorrhage as a Sequela of COVID-19. Cureus. 2020 Sep 14; 12(9):e10447. Daid SS, Toribio AD, Lakshmanan S, Sadda A, Epstein A. PMID: 33072456; PMCID: PMC7557520.
      View in: PubMed   Mentions: 4  
    18. Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma. Biomaterials. 2020 12; 262:120338. Lee C, Peddi S, Anderson C, Su H, Cui H, Epstein AL, MacKay JA. PMID: 32916604; PMCID: PMC8386582.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    19. Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations. Antibodies (Basel). 2020 Jun 10; 9(2). Boune S, Hu P, Epstein AL, Khawli LA. PMID: 32532067; PMCID: PMC7345016.
      View in: PubMed   Mentions: 35  
    20. Comparative Analysis of Cytokines of Tumor Cell Lines, Malignant and Benign Effusions Around Breast Implants. Aesthet Surg J. 2020 05 16; 40(6):630-637. Kadin ME, Morgan J, Kouttab N, Xu H, Adams WP, Glicksman C, McGuire P, Sieber D, Epstein AL, Miranda RN, Clemens MW. PMID: 31589747.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    21. A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models. Clin Cancer Res. 2020 07 15; 26(14):3694-3706. Zheng L, Ren L, Kouhi A, Khawli LA, Hu P, Kaslow HR, Epstein AL. PMID: 32273277.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    22. Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract. Leukemia. 2020 05; 34(5):1467-1471. Hu G, Phillips JL, Dasari S, Jacobs HK, Luchtel RA, Oishi N, Hundal T, Ahmed NH, Satou A, Epstein AL, Bennani NN, Nowakowski GS, Murray JA, Feldman AL. PMID: 31836854; PMCID: PMC7196010.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    23. Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy. Mol Ther. 2020 02 05; 28(2):536-547. Shi X, Cheng Q, Hou T, Han M, Smbatyan G, Lang JE, Epstein AL, Lenz HJ, Zhang Y. PMID: 31843452; PMCID: PMC7001084.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansAnimalsCells
    24. Expression of the luteinizing hormone receptor (LHR) in ovarian cancer. BMC Cancer. 2019 Nov 15; 19(1):1114. Xiong S, Mhawech-Fauceglia P, Tsao-Wei D, Roman L, Gaur RK, Epstein AL, Pinski J. PMID: 31729966; PMCID: PMC6857310.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    25. OX40L-JAG1-Induced Expansion of Lineage-Stable Regulatory T Cells Involves Noncanonical NF-κB Signaling. J Immunol. 2019 12 15; 203(12):3225-3236. Kumar P, Lele SS, Ragothaman VK, Raghunathan D, Epstein AL, Chiba S, Prabhakar BS. PMID: 31704879; PMCID: PMC6904432.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    26. Generation of a Monoclonal Antibody to Detect Elastin-like Polypeptides. Biomacromolecules. 2019 08 12; 20(8):2942-2952. Kouhi A, Yao Z, Zheng L, Li Z, Hu P, Epstein AL, MacKay JA. PMID: 31276401; PMCID: PMC7219198.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsPHPublic Health
    27. Antibodies to Brewer's Yeast in Rheumatoid Arthritis. Cureus. 2019 May 17; 11(5):e4691. Lichtenstein JR, Epstein AL. PMID: 31333917; PMCID: PMC6636702.
      View in: PubMed   Mentions:
    28. Costimulation of type-2 innate lymphoid cells by GITR promotes effector function and ameliorates type 2 diabetes. Nat Commun. 2019 02 12; 10(1):713. Galle-Treger L, Sankaranarayanan I, Hurrell BP, Howard E, Lo R, Maazi H, Lewis G, Banie H, Epstein AL, Hu P, Rehan VK, Gilliland FD, Allayee H, Soroosh P, Sharpe AH, Akbari O. PMID: 30755607; PMCID: PMC6372786.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCells
    29. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018 05 22; 9(1):2024. Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, Meyers R, Gao G, Cherniack A, Louissaint A, Nardi V, Thorner AR, Long H, Qiu X, Morgan EA, Dorfman DM, Fiore D, Jang J, Epstein AL, Dogan A, Zhang Y, Horwitz SM, Jacobsen ED, Santiago S, Ren JG, Guerlavais V, Annis DA, Aivado M, Saleh MN, Mehta A, Tsherniak A, Root D, Vazquez F, Hahn WC, Inghirami G, Aster JC, Weinstock DM, Koch R. PMID: 29789628; PMCID: PMC5964252.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    30. IL-13 is produced by tumor cells in breast implant-associated anaplastic large cell lymphoma: implications for pathogenesis. Hum Pathol. 2018 08; 78:54-62. Kadin ME, Morgan J, Xu H, Epstein AL, Sieber D, Hubbard BA, Adams WP, Bacchi CE, Goes JCS, Clemens MW, Medeiros LJ, Miranda RN. PMID: 29689246.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    31. Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation. Cell Mol Immunol. 2019 02; 16(2):138-153. Kumar P, Marinelarena A, Raghunathan D, Ragothaman VK, Saini S, Bhattacharya P, Fan J, Epstein AL, Maker AV, Prabhakar BS. PMID: 29578532; PMCID: PMC6355936.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    32. Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma. Int J Mol Sci. 2017 Dec 20; 18(12). Zheng L, Hu P, Wolfe B, Gonsalves C, Ren L, Khawli LA, Kaslow HR, Epstein AL. PMID: 29261129; PMCID: PMC5751371.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    33. PKC-ѳ is dispensable for OX40L-induced TCR-independent Treg proliferation but contributes by enabling IL-2 production from effector T-cells. Sci Rep. 2017 07 26; 7(1):6594. Alharshawi K, Marinelarena A, Kumar P, El-Sayed O, Bhattacharya P, Sun Z, Epstein AL, Maker AV, Prabhakar BS. PMID: 28747670; PMCID: PMC5529425.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    34. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations. Proc Natl Acad Sci U S A. 2017 04 11; 114(15):3975-3980. Chen J, Zhang Y, Petrus MN, Xiao W, Nicolae A, Raffeld M, Pittaluga S, Bamford RN, Nakagawa M, Ouyang ST, Epstein AL, Kadin ME, Del Mistro A, Woessner R, Jaffe ES, Waldmann TA. PMID: 28356514; PMCID: PMC5393253.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    35. Soluble OX40L and JAG1 Induce Selective Proliferation of Functional Regulatory T-Cells Independent of canonical TCR signaling. Sci Rep. 2017 01 03; 7:39751. Kumar P, Alharshawi K, Bhattacharya P, Marinelarena A, Haddad C, Sun Z, Chiba S, Epstein AL, Prabhakar BS. PMID: 28045060; PMCID: PMC5206631.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    36. Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins. J Immunol Res. 2016; 2016:2342187. Smith A, Manoli H, Jaw S, Frutoz K, Epstein AL, Khawli LA, Theil FP. PMID: 27579329; PMCID: PMC4992793.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    37. Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice. Autoimmunity. 2016 08; 49(5):298-311. Haddad CS, Bhattacharya P, Alharshawi K, Marinelarena A, Kumar P, El-Sayed O, Elshabrawy HA, Epstein AL, Prabhakar BS. PMID: 27245356; PMCID: PMC5042830.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    38. Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Aesthet Surg J. 2016 Jul; 36(7):773-81. Kadin ME, Deva A, Xu H, Morgan J, Khare P, MacLeod RA, Van Natta BW, Adams WP, Brody GS, Epstein AL. PMID: 26979456.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    39. Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models. Cancer Immunol Immunother. 2016 May; 65(5):511-23. Jang JK, Khawli LA, Canter DC, Hu P, Zhu TH, Wu BW, Angell TE, Li Z, Epstein AL. PMID: 26960932; PMCID: PMC4841721.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    40. Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant. J Immunother Cancer. 2016; 4:11. Andersen BM, Xia J, Epstein AL, Ohlfest JR, Chen W, Blazar BR, Pennell CA, Olin MR. PMID: 26885373; PMCID: PMC4755027.
      View in: PubMed   Mentions: 13     Fields:    
    41. Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent. Thyroid. 2016 Mar; 26(3):381-9. Angell TE, Lechner MG, Smith AM, Martin SE, Groshen SG, Maceri DR, Singer PA, Epstein AL. PMID: 26756227; PMCID: PMC4790214.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    42. Phase 1 Dose-Escalation Study with LEC/chTNT-3 and Toceranib Phosphate (Palladia®) in Dogs with Spontaneous Malignancies. J Cancer Sci Ther. 2015; 7(6):167-174. Jang JK, Chretin J, Bruyette D, Hu P, Epstein AL. PMID: 26635918; PMCID: PMC4666026.
      View in: PubMed   Mentions: 1  
    43. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg. 2015 Mar; 135(3):695-705. Brody GS, Deapen D, Taylor CR, Pinter-Brown L, House-Lightner SR, Andersen JS, Carlson G, Lechner MG, Epstein AL. PMID: 25490535.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    44. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014 Dec 01; 20(23):6034-44. Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL. PMID: 25294906; PMCID: PMC4252612.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCells
    45. Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA. Expert Rev Anticancer Ther. 2014 Oct; 14(10):1243-9. Bryan RA, Jiang Z, Jandl T, Strauss J, Koba W, Onyedika C, Morgenstern A, Bruchertseifer F, Epstein AL, Dadachova E. PMID: 25156106.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    46. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid. 2014 Sep; 24(9):1385-93. Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. PMID: 24955518; PMCID: PMC4148060.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    47. A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody. ACS Nano. 2014 Mar 25; 8(3):2064-76. Aluri SR, Shi P, Gustafson JA, Wang W, Lin YA, Cui H, Liu S, Conti PS, Li Z, Hu P, Epstein AL, MacKay JA. PMID: 24484356; PMCID: PMC4004287.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    48. Boron neutron capture therapy as new treatment for clear cell sarcoma: trial on different animal model. Appl Radiat Isot. 2014 Jun; 88:59-63. Andoh T, Fujimoto T, Sudo T, Suzuki M, Sakurai Y, Sakuma T, Moritake H, Sugimoto T, Takeuchi T, Sonobe H, Epstein AL, Fukumori Y, Ono K, Ichikawa H. PMID: 24389062.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    49. CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma. J Immunol. 2014 Jan 01; 192(1):224-33. Murphy KA, Erickson JR, Johnson CS, Seiler CE, Bedi J, Hu P, Pluhar GE, Epstein AL, Ohlfest JR. PMID: 24293627; PMCID: PMC4068509.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    50. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother. 2013 Nov-Dec; 36(9):477-89. Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL. PMID: 24145359; PMCID: PMC3910494.
      View in: PubMed   Mentions: 179     Fields:    Translation:HumansAnimalsCells
    51. Cytoreductive chemotherapy improves the biodistribution of antibodies directed against tumor necrosis in murine solid tumor models. Mol Cancer Ther. 2013 Dec; 12(12):2827-36. Jang JK, Khawli LA, Park R, Wu BW, Li Z, Canter D, Conti PS, Epstein AL. PMID: 24130055; PMCID: PMC3929394.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    52. Modulation of Treg cells/T effector function by GITR signaling is context-dependent. Eur J Immunol. 2013 Sep; 43(9):2421-9. Ephrem A, Epstein AL, Stephens GL, Thornton AM, Glass D, Shevach EM. PMID: 23722868.
      View in: PubMed   Mentions: 54     Fields:    Translation:AnimalsCells
    53. Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma. Head Neck Oncol. 2013 Feb 27; 5(3):24. Russell S, Angell T, Lechner M, Liebertz D, Correa A, Sinha U, Kokot N, Epstein A. PMID: 24723971; PMCID: PMC3979926.
      View in: PubMed   Mentions: 66     Fields:    
    54. Establishment and characterization of a new human extragonadal germ cell line, SEM-1, and its comparison with TCam-2 and JKT-1. Urology. 2013 Feb; 81(2):464.e1-9. Russell SM, Lechner MG, Mokashi A, Megiel C, Jang JK, Taylor CR, Looijenga LH, French CA, Epstein AL. PMID: 23374840; PMCID: PMC4179199.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    55. Generation of tumor-targeted antibody-CpG conjugates. J Immunol Methods. 2013 Mar 29; 389(1-2):45-51. Li Z, Jang JK, Lechner MG, Hu P, Khawli L, Scannell CA, Epstein AL. PMID: 23279945.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    56. A rare case of noninsulinoma pancreatogenous hypoglycemia syndrome. Case Rep Gastrointest Med. 2012; 2012:164305. Nadelson J, Epstein A. PMID: 23213581; PMCID: PMC3508526.
      View in: PubMed   Mentions: 3  
    57. Survival signals and targets for therapy in breast implant-associated ALK--anaplastic large cell lymphoma. Clin Cancer Res. 2012 Sep 01; 18(17):4549-59. Lechner MG, Megiel C, Church CH, Angell TE, Russell SM, Sevell RB, Jang JK, Brody GS, Epstein AL. PMID: 22791880.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    58. An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas. Clin Cancer Res. 2012 Sep 01; 18(17):4657-68. Murphy KA, Lechner MG, Popescu FE, Bedi J, Decker SA, Hu P, Erickson JR, O'Sullivan MG, Swier L, Salazar AM, Olin MR, Epstein AL, Ohlfest JR. PMID: 22781551; PMCID: PMC3432688.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    59. The perichromatin region of the plant cell nucleus is the area with the strongest co-localisation of snRNA and SR proteins. Planta. 2012 Aug; 236(2):715-26. Niedojadlo J, Mikulski Z, Delenko K, Szmidt-Jaworska A, Smolinski DJ, Epstein AL. PMID: 22526497; PMCID: PMC3404291.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    60. Unique approach for B lymphoma therapy. Blood. 2012 Apr 19; 119(16):3647-8. Epstein AL. PMID: 22517869.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    61. Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators. J Clin Cell Immunol. 2012; Suppl 5:004. Stathopoulos A, Pretto C, Devillers L, Pierre D, Hofman FM, Epstein AL, Farghadani H, Kruse CA, Jadus MR, Chen TC, Schijns VE. PMID: 24955288; PMCID: PMC4062195.
      View in: PubMed   Mentions: 2  
    62. Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy. 2011 Nov; 3(11):1317-40. Lechner MG, Russell SM, Bass RS, Epstein AL. PMID: 22053884; PMCID: PMC3226699.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    63. USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics. Oral Oncol. 2011 Sep; 47(9):810-7. Russell SM, Lechner MG, Gong L, Megiel C, Liebertz DJ, Masood R, Correa AJ, Han J, Puri RK, Sinha UK, Epstein AL. PMID: 21719345; PMCID: PMC3164740.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    64. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med. 2011 Jun 09; 9:90. Lechner MG, Megiel C, Russell SM, Bingham B, Arger N, Woo T, Epstein AL. PMID: 21658270; PMCID: PMC3128058.
      View in: PubMed   Mentions: 110     Fields:    Translation:HumansCells
    65. Evaluation of BPA uptake in clear cell sarcoma (CCS) in vitro and development of an in vivo model of CCS for BNCT studies. Appl Radiat Isot. 2011 Dec; 69(12):1713-6. Fujimoto T, Andoh T, Sudo T, Fujita I, Imabori M, Moritake H, Sugimoto T, Sakuma Y, Takeuchi T, Sonobe H, Epstein AL, Akisue T, Kirihata M, Kurosaka M, Fukumori Y, Ichikawa H. PMID: 21354804.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    66. A new mechanism for blocking myeloid-derived suppressor cells by CpG. Clin Cancer Res. 2011 Apr 01; 17(7):1645-8. Lechner MG, Epstein AL. PMID: 21288925; PMCID: PMC4237605.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    67. Rapidly fatal pulmonary fibrosis in a patient with psoriatic arthritis treated with adalimumab. J Rheumatol. 2011 Feb; 38(2):398-9. Cohen JV, Capell BC, Kinniry PA, Epstein AL. PMID: 21285183.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    68. Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity. Cancer. 2011 Apr 01; 117(7):1478-89. Lechner MG, Lade S, Liebertz DJ, Prince HM, Brody GS, Webster HR, Epstein AL. PMID: 21425149; PMCID: PMC4175713.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    69. A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Res. 2010 Nov 15; 70(22):9041-52. Pardee AD, McCurry D, Alber S, Hu P, Epstein AL, Storkus WJ. PMID: 21045144; PMCID: PMC3058673.
      View in: PubMed   Mentions: 24     Fields:    Translation:AnimalsCells
    70. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010 Aug 15; 185(4):2273-84. Lechner MG, Liebertz DJ, Epstein AL. PMID: 20644162; PMCID: PMC2923483.
      View in: PubMed   Mentions: 305     Fields:    Translation:HumansCells
    71. Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1. Head Neck Oncol. 2010 Feb 22; 2:5. Liebertz DJ, Lechner MG, Masood R, Sinha UK, Han J, Puri RK, Correa AJ, Epstein AL. PMID: 20175927; PMCID: PMC2841166.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    72. Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity. J Immunol. 2009 May 01; 182(9):5430-8. Phares TW, Ramakrishna C, Parra GI, Epstein A, Chen L, Atkinson R, Stohlman SA, Bergmann CC. PMID: 19380790; PMCID: PMC2909606.
      View in: PubMed   Mentions: 55     Fields:    Translation:AnimalsCells
    73. Influence of an educational seminar on use of disease activity measurements by rheumatologists in treatment of rheumatoid arthritis. J Rheumatol. 2009 Mar; 36(3):532-8. Hamburger MI, Hamburger FH, Bergman JM, Epstein A, Brown A. PMID: 19208595.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    74. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. J Immunother. 2008 Apr; 31(3):235-45. Sadun RE, Hsu WE, Zhang N, Nien YC, Bergfeld SA, Sabzevari H, Lutsiak ME, Khawli L, Hu P, Epstein AL. PMID: 18317364.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    75. Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer. Clin Cancer Res. 2008 Jan 15; 14(2):579-88. Hu P, Arias RS, Sadun RE, Nien YC, Zhang N, Sabzevari H, Lutsiak ME, Khawli LA, Epstein AL. PMID: 18223234.
      View in: PubMed   Mentions: 18     Fields:    Translation:AnimalsCells
    76. Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients. Cancer Immunol Immunother. 2008 May; 57(5):677-84. Wang H, Cao C, Li B, Chen S, Yin J, Shi J, Ye D, Tao Q, Hu P, Epstein A, Ju D. PMID: 17934732.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    77. Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res. 2007 Jul 01; 13(13):4016-25. Sadun RE, Sachsman SM, Chen X, Christenson KW, Morris WZ, Hu P, Epstein AL. PMID: 17606736.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    78. Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors. Cancer Biother Radiopharm. 2007 Jun; 22(3):342-56. Zhang N, Khawli LA, Hu P, Epstein AL. PMID: 17651040.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    79. RA8, a human anti-CD25 antibody against human Treg cells. Hybridoma (Larchmt). 2007 Jun; 26(3):119-30. Arias RS, Flanagan ML, Miller KD, Nien YC, Hu P, Gray D, Khawli LA, Epstein AL. PMID: 17600493.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    80. Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines. Leuk Lymphoma. 2007 May; 48(5):944-56. Tobin E, Denardo G, Zhang N, Epstein AL, Liu C, Denardo S. PMID: 17487739.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    81. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin Cancer Res. 2007 May 01; 13(9):2758-67. Zhang N, Sadun RE, Arias RS, Flanagan ML, Sachsman SM, Nien YC, Khawli LA, Hu P, Epstein AL. PMID: 17460060.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    82. Soluble Fc fusion proteins for biomedical research. Methods Mol Biol. 2007; 378:33-52. Flanagan ML, Arias RS, Hu P, Khawli LA, Epstein AL. PMID: 18605076.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCellsPHPublic Health
    83. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors. J Immunother. 2006 Jul-Aug; 29(4):425-35. Liu A, Hu P, Khawli LA, Epstein AL. PMID: 16799338.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    84. H60/TNT-3 fusion protein activates NK cells in vitro and improves immunotherapeutic outcome in murine syngeneic tumor models. J Immunother. 2006 May-Jun; 29(3):274-83. Flanagan ML, Khawli LA, Hu P, Epstein AL. PMID: 16699370.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    85. 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm. 2006 Feb; 21(1):5-14. Yu L, Ju DW, Chen W, Li T, Xu Z, Jiang C, Chen S, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein AL. PMID: 16480326.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    86. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin Cancer Res. 2005 Dec 01; 11(23):8492-502. Liu A, Hu P, Khawli LA, Epstein AL. PMID: 16322313.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    87. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res. 2005 Aug 15; 11(16):5971-80. Zhang N, Khawli LA, Hu P, Epstein AL. PMID: 16115941.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    88. NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):3084-93. Khawli LA, Hu P, Epstein AL. PMID: 15837764.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    89. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol. 2005 Mar 01; 23(7):1538-47. Chen S, Yu L, Jiang C, Zhao Y, Sun D, Li S, Liao G, Chen Y, Fu Q, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein AL, Ju DW. PMID: 15735129.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    90. chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors. Hybrid Hybridomics. 2004 Feb; 23(1):1-10. Li J, Hu P, Khawli LA, Yun A, Epstein AL. PMID: 15000842.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    91. Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody. Cancer Biother Radiopharm. 2003 Dec; 18(6):931-40. Khawli LA, Alauddin MM, Hu P, Epstein AL. PMID: 14969605.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    92. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Cancer Res. 2003 Dec 01; 63(23):8384-92. Li J, Hu P, Khawli LA, Epstein AL. PMID: 14679000.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    93. Monoclonal LYM-1 antibody-dependent cytolysis by human neutrophils exposed to GM-CSF: auto-regulation of target cell attack by cathepsin G. J Leukoc Biol. 2004 Jan; 75(1):99-105. Ottonello L, Epstein AL, Mancini M, Dapino P, Dallegri F. PMID: 14525961.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    94. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res. 2003 Aug 15; 63(16):5046-53. Hu P, Yan J, Sharifi J, Bai T, Khawli LA, Epstein AL. PMID: 12941833.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    95. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies. Hybrid Hybridomics. 2003 Aug; 22(4):197-207. Mizokami MM, Hu P, Khawli LA, Li J, Epstein AL. PMID: 14511565.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    96. LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors. J Immunother. 2003 Jul-Aug; 26(4):320-31. Li J, Hu P, Khawli LA, Epstein AL. PMID: 12843794.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    97. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT). Cancer Biother Radiopharm. 2003 Jun; 18(3):339-53. Biela BH, Khawli LA, Hu P, Epstein AL. PMID: 12954121.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    98. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst. 2003 May 21; 95(10):741-9. Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA. PMID: 12759392.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    99. Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood. 2003 Jun 15; 101(12):4853-61. Hu P, Mizokami M, Ruoff G, Khawli LA, Epstein AL. PMID: 12609842.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    100. Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors. Hybrid Hybridomics. 2003 Feb; 22(1):1-9. Khawli LA, Biela B, Hu P, Epstein AL. PMID: 12713684.
      View in: PubMed   Mentions: 11     Fields:    Translation:Animals
    101. Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins. Hybrid Hybridomics. 2002 Dec; 21(6):421-32. Sharifi J, Khawli LA, Hu P, Li J, Epstein AL. PMID: 12573106.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    102. Stable, genetically engineered F(ab')(2) fragments of chimeric TNT-3 expressed in mammalian cells. Hybrid Hybridomics. 2002 Feb; 21(1):11-8. Khawli LA, Biela BH, Hu P, Epstein AL. PMID: 11991812.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells